XOMA Royalty Corp Dossier
Qualitative Analysis
Business overview
XOMA Royalty Corp (NASDAQ: XOMA) operates as a specialized biotechnology royalty aggregator. The company's business model centers on acquiring the potential future economics—specifically milestone and royalty payments—associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. In exchange for these future economic rights, XOMA provides non-dilutive, non-recourse funding to biotech developers, helping them advance their internal pipelines. XOMA maintains a highly capital-efficient structure where substantially all research, development, and commercialization costs are borne by the assets' sponsors, allowing XOMA to operate with a lean corporate infrastructure. As of early 2026, XOMA's expansive portfolio includes economic interests in over 120 assets in active development, spanning commercial-stage products and late-stage clinical candidates. On April 27, 2026, XOMA entered into a definitive agreement to be acquired by peer royalty aggregator Ligand Pharmaceuticals for $39.00 per share in cash, representing an equity value of approximately $739 million, plus a Contingent Value Right (CVR) related to pending litigation.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning from a traditional drug development biotechnology company to a pure-play royalty aggregator, focusing on acquiring economic rights to future milestone and royalty payments associated with pre-commercial and commercial therapeutic candidates.
Expected impact: Builds a diversified portfolio of over 120 assets to generate long-term compounding cash flows and reduce single-asset clinical development risk.
Entering into a definitive merger agreement to be acquired by peer royalty aggregator Ligand Pharmaceuticals for $39.00 per share in cash.
Expected impact: Combines XOMA's portfolio of over 120 assets with Ligand's platform, creating a leading biopharma royalty aggregator with over 200 total assets and immediate financial accretion.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Generation Bio's cell-targeted lipid nanoparticle (ctLNP) delivery platform for siRNA and other nucleic acid therapies, securing potential milestone and royalty payments under an existing collaboration with Moderna.
Financial impact: Stockholders received $4.2913 per share in cash plus one non-transferable Contingent Value Right (CVR) per share for potential future payments from the Moderna collaboration and platform licensing.
Acquisition of clinical-stage biotech Lava Therapeutics to secure economic rights to partnered assets with Pfizer and Johnson & Johnson.
Financial impact: XOMA agreed to pay $1.16 per share in cash, with potential for up to $0.08 more per share, plus CVRs representing 75% of proceeds from partnered assets.
Acquisition of vaccine developer HilleVax to expand XOMA's pre-commercial royalty and milestone portfolio.
Financial impact: Assumed lease obligations of approximately $42.3 million recorded as restricted cash at year-end 2025.
Strategic Partnerships
Amended collaboration securing low to mid-single-digit royalties and up to $852.6 million in potential milestones across nine development-stage assets, including osavampator and volixibat.
Terms: Entitles XOMA to potential milestones of up to $852.6 million plus low to mid-single-digit royalties on commercial sales.